Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Capital Expenditures: 2020-2024

Historic Capital Expenditures for Janux Therapeutics (JANX) over the last 5 years, with Dec 2024 value amounting to $359,000.

  • Janux Therapeutics' Capital Expenditures rose 272.00% to $93,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $979,000, marking a year-over-year increase of 17.67%. This contributed to the annual value of $359,000 for FY2024, which is 80.59% down from last year.
  • According to the latest figures from FY2024, Janux Therapeutics' Capital Expenditures is $359,000, which was down 80.59% from $1.9 million recorded in FY2023.
  • In the past 5 years, Janux Therapeutics' Capital Expenditures registered a high of $6.4 million during FY2022, and its lowest value of $147,000 during FY2020.
  • Moreover, its 3-year median value for Capital Expenditures was $1.9 million (2023), whereas its average is $2.9 million.
  • In the last 5 years, Janux Therapeutics' Capital Expenditures soared by 908.16% in 2021 and then slumped by 80.59% in 2024.
  • Yearly analysis of 5 years shows Janux Therapeutics' Capital Expenditures stood at $147,000 in 2020, then skyrocketed by 908.16% to $1.5 million in 2021, then skyrocketed by 334.89% to $6.4 million in 2022, then plummeted by 71.30% to $1.9 million in 2023, then tumbled by 80.59% to $359,000 in 2024.